Clinical trial Archives

News and Trends 8 Jun 2023

Minoryx can start phase 3 trial for cerebral adrenoleukodystrophy patients

Spanish-headquartered Minoryx Therapeutics says the U.S. Food and Drug Administration (FDA) has approved its phase 3 clinical trial (CALYX) of lead candidate leriglitazone, to treat adult male X-linked adrenoleukodystrophy (X-ALD) patients with cerebral adrenoleukodystrophy (cALD). X-ALD is an orphan neurodegenerative disease. The global incidence of X-ALD is approximately six to eight per 100,000 live births. […]

June 8, 2023 - 4 minutesmins - By Jim Cornall

Best in Biotech 6 Jun 2023

Ten Swedish companies spearheading the country’s biotech scene

Known for its abundant forests, smorgasbords and not to mention the famed Europop group ABBA, Sweden has a thriving economy that largely depends on manufacturing and exports. And the country’s life science sector having recorded a net turnover of almost SEK 365 billion ($33.5 million) in 2020, is ever-growing. Home to more than 1,000 life […]

June 6, 2023 - 10 minutesmins - By David Cox

News and Trends 6 Jun 2023

Head and neck cancer data presented at ASCO 2023

Results from promising trials in the fight against head and neck cancer have been presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation, a provider of IT, network and AI technologies, announced new […]

June 6, 2023 - 7 minutesmins - By Jim Cornall

Podcast 2 Jun 2023

Beyond Biotech podcast 48

BioInvent International AB, a Swedish biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, recently announced positive phase 1a data on the oncolytic virus BT-001 for the treatment of solid tumors. BioInvent currently has four […]

June 2, 2023 - 1 minutemin - By Jim Cornall

News and Trends 2 Jun 2023

Anocca raises $36.6M for large-scale development of cancer cell therapies

Anocca AB has raised SEK 400 million ($36.6 million) to further develop the discovery and manufacture of next generation cell therapies for cancer on an industrial scale. It will also allow Anocca to progress its first products into clinical trials. The financing brings together a group of existing and new investors, including Mellby Gård, AMF, […]

June 2, 2023 - 4 minutesmins - By Jim Cornall

Best in Biotech 30 May 2023

Five latest advancements in endometriosis research

Affecting around 190 million women and girls globally, endometriosis is caused by the growth of tissue – similar to those in the uterine lining – outside the uterus, leading to debilitating pelvic pain during sex and periods – which is usually a heavy flow. As 50% of endometriosis patients deal with fertility issues, the economic […]

May 30, 2023 - 9 minutesmins - By Roohi Mariam Peter

News and Trends 30 May 2023

Molecular Partners presenting positive solid tumor data

Molecular Partners AG will present additional positive data from the ongoing phase 1 study of MP0317, a CD40 agonist designed to activate immune cells specifically within the tumor microenvironment by anchoring to fibroblast activation protein (FAP), at the 2023 ASCO (American Society of Clinical Oncology) annual meeting, June 2 to 6 in Chicago, U.S. The […]

May 30, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 26 May 2023

Transgene and BioInvent report positive solid tumor results

Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, have announced positive phase Ia data on the oncolytic virus BT-001 for the treatment of solid tumors. Treatment with single agent […]

May 26, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 May 2023

FDA approval for Rznomics’ glioblastoma treatment trial

Rznomics Inc., a South Korea based biopharmaceutical company specializing in the development of RNA-based gene therapeutics, has received phase 1/2a IND approval from the U.S. FDA for its glioblastoma multiforme (GBM) treatment. RZ-001 initially obtained IND approval for hepatocellular carcinoma (HCC), but Rznomics also found pre-clinical efficacy in GBM models and submitted the IND for […]

May 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 May 2023

Vicore reports new data from idiopathic pulmonary fibrosis study

Vicore Pharma Holding AB (publ), has announced an updated interim analysis of its AIR phase 2a trial with C21 in idiopathic pulmonary fibrosis (IPF). With 51 patients enrolled, the data demonstrates that C21 has the potential to transform the treatment of IPF and restore lung function. The disease is currently considered to be incurable and […]

May 23, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 23 May 2023

Take part in a clinical trial? Sure, just pay me

The majority of people in the U.K. (68%) would consider taking part in a clinical trial, it has been revealed today, while half of Brits would also be willing to take part in an early phase clinical trial. Financial payment is the most popular motivation for taking part in a clinical trial, but discovering new […]

May 23, 2023 - 4 minutesmins - By Jim Cornall

Best in Biotech 22 May 2023

Five recent advancements in arthritis research over the past year

Today, more than 350 million people across the world – and nearly a quarter of American adults – have arthritis. A condition characterized by pain, inflammation and stiffness in the joints – often owing to a hyperactive immune system causing the body to attack its own joint tissues, in the case of rheumatoid arthritis – […]

May 22, 2023 - 8 minutesmins - By Roohi Mariam Peter

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clinical trial

Minoryx can start phase 3 trial for cerebral adrenoleukodystrophy patients

Ten Swedish companies spearheading the country’s biotech scene

Head and neck cancer data presented at ASCO 2023

Beyond Biotech podcast 48

Anocca raises $36.6M for large-scale development of cancer cell therapies

Five latest advancements in endometriosis research

Molecular Partners presenting positive solid tumor data

Transgene and BioInvent report positive solid tumor results

FDA approval for Rznomics’ glioblastoma treatment trial

Vicore reports new data from idiopathic pulmonary fibrosis study

Take part in a clinical trial? Sure, just pay me

Five recent advancements in arthritis research over the past year

Subscribe to our newsletter to get the latest biotech news!